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Introduction
Post-operative atrial fibrillation (POAF) is the most prevalent 
complication after cardiac or lung surgery, occurring in about 
20-50 percent of  these patients [1-5]. This event often leads to 
increased morbidity, thromboembolisms, strokes and long-term 
mortality resulting in recurring hospitalizations and increased 
costs. Often the cause(s) of  POAF is not known. Age, previous 
history of  atrial fibrillation (AF), hypertension, diabetes, 
myocardial infarction, valvular heart disease, left ventricular 
hypertrophy, obesity, excessive drinking of  alcohol and excessive 
smoking present great risk factors for development of  POAF [1-
5]. According to a number of  reports, the incidence of  cerebral 
infarction and heart failure can increase two-four - fold after PAOF 
[1-5]. Added to this, are a number of  growing autopsy studies 
which demonstrate that many of  the PAOF patients, who have 
died, have considerable atherosclerotic plaques on the walls of  
the coronary vessels leading to the idea that inflammatory events 
probably play an important role in the PAOF syndrome [5]. POAF 
is usually managed by digoxin, calcium channel blockers, beta-
blockers, quinidine, amiodarone, direct current cardioversion, 
catheter ablation inside the heart, or appropriate rate control 
techniques to restore rhythm to normal [1-5]. Although digoxin 
is often utilized, it can present direct risks for POAF patients 
and has been associated with increased hospitalizations and 
mortalities [6, 7]. Such data has raised serious concerns about 
use of  digoxin, one of  our oldest and most controversial drugs 
. Ever since 1935 [8], digoxin and cardiac glycosides have been 
known to deplete the human body and heart of  magnesium (Mg) 
[for review, see [9]]. Several studies have suggested that use of  
intravenous magnesium sulfate may be better than either beta-
blockers, calcium channel blockers, or amiodarone [1, 5, 10-12]. 
This concept is currently under investigation by several groups in 
the USA and Europe.
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Why use intravenous Mg2+ ?
Mg is a co-factor for more than 500 enzymes, and is the second 
most abundant intracellular cation after potassium. It is vital in 
numerous physiological , cellular and biochemical functions 
necessary for life [for reviews, see [13-15]].
Approximately 35 years ago, our laboratory suggested a 
progressive, dietary deficiency and/or metabolic-induced loss of  
Mg from the body (and heart), particularly during development 
of  coronary arteries, could lead to coronary arterial vasospasm, 
arrhythmias, and sudden-cardiac death [16, 17]. Ever since this 
work was published, a number of  clinical studies have been 
done and published which support this hypothesis, at least 
in adults [18-23]. Disturbances in diet are known to produce 
inflammatory lesions, promote lipid deposition and accelerated 
growth, and transformation of  the smooth muscle cells in the 
vascular walls [9, 13, 14, 24-28]. Reduction in dietary Mg intake 
has been demonstrated , experimentally, to result in atherogenesis, 
hypertension, cardiac dysfunctions, inflammations, and stroke 
of  different types [9, 13-15, 29-33]; most of  these phenomena 
usually being observed in patients scheduled for cardiac and lung 
surgeries. Hypermagnesemic diets have been shown to ameliorate 
atherogenesis, hypertension, cardiac dysfunctions, strokes and 
certain inflammatory conditions often found in patients scheduled 
for cardiac and lung surgeries [9, 13, 14, 24, 27-33]. In the Western 
World, dietary intake of  Mg is subnormal, with shortfalls of  
between 65 and 225 mg of  Mg/day, depending upon geographic 
region [9, 13-15, 30, 34, 35]. Newly compiled NHANES data 
indicate that approximately 65% of  the American population is Mg 
deficient [36]. Low Mg content in drinking water, found in areas 
of  soft water and Mg-poor soil, is associated with high incidences 
of  ischemic heart disease (IHD), severe atherosclerosis, coronary 
vasospasm, hypertension, hyperlipidemia, and sudden-cardiac 
death [37- 44]. The myocardial level of  Mg has consistently been 
observed to be lower in subjects dying from IHD and sudden-
cardiac death in soft water areas [9, 13, 16, 17, 24, 39, 43]. 
Using sensitive, specific Mg2+- ion electrodes, it has been shown 
that patients with IHD, patients scheduled for cardiac surgery or 
lung surgery, patients in cardiac failure, and patients with severe 
atherosclerosis exhibit significant depletion of  serum/plasma and 
tissue levels of  ionized, but not usually total Mg [15, 27, 33, 45-
65]. Moreover, dietary deficiency of  Mg, under very controlled 
laboratory conditions, in rats and rabbits has been shown to 
cause vascular remodeling concomitant with atherogenesis and 
hypertension (e.g., arteriolar wall hypertrophy and alterations in 
arterial wall matrices) of  unknown origin [67-69].
Mg2+ modulates sphingolipid pathways in cardiac 
and vascular smooth muscle cells
Although Mg depletion has long been known to result in cellular 
Ca2+-overload in cardiac and vascular smooth muscles (VSM) [70-
73], and Mg can act as a natural Ca2+ channel blocker [71-73], 
recent studies indicate that Mg2+ modulates sphingolipid pathways 
in both cardiac and VSM cells [27, 43, 44, 74-86]. Ceramides 
are sphingolipids known to be released as a consequence of  
sphingomyelinase (SMase) acting on sphingomyelin (SM), a 
component of  all cell membranes, or as a consequence of  the 
activation of  serine palmitoyl transferase 1 and 2 (SPT 1 and 
SPT 2) (a de novo synthetic pathway) [87]. Ceramides are now 
thought to play important roles in fundamental processes such 
as inflammation, angiogenesis, membrane-receptor functions, 
cell proliferation, microcirculatory functions, cell adhesion, 
immunogenic responses, excitation-contraction coupling events 
in smooth muscles, and cell death (i.e., apoptosis) [27, 43, 44, 
74-92]. SPT 1 and SPT 2 are the rate-limiting enzymes in the 
biosynthesis of  sphingolipids [87]. More than 25 years ago, it was 
first demonstrated that SPT activity was increased in aortas of  
rabbits fed a high-cholesterol diet [93]. A short time after these 
latter studies were published, two of  us showed that dietary 
deficiency of  Mg, in levels found commonly in Western World 
diets, vastly increased atherosclerotic plaque formations in rabbits 
fed high -cholesterol diets, whereas high dietary levels of  Mg 
inhibited plaque formations [28]. SPT is a hetrodimer of  53-kDa 
SPT-1 and 63-kDa SPT-2 subunits [87], both of  which are bound 
to the endoplasmic reticulum [94]. An upregulation of  SPT has 
been hypothesized to play a role in apoptosis, cell death events 
taking place in atherogenesis [79, 95].
 
Recently, we reported that Mg deficient (MgD) diets given to 
rats for only 21 days results in upregulation of  SMases (i.e., 
N-SMase, acid--SMase, and alkaline SMase), ceramide synthase, 
sphingomyelin synthase, SPT-1 and SPT-2 in a variety of  
cardiovascular tissues and cells as well decreased levels of  SM and 
phosphatidylcholine (PC) [79-82, 84-86]. We also noted that MgD 
diets resulted in fragmentation of  DNA [81, 86, 96], release/
generation of  a number of  cytokines (and chemokines) [84], a 
release of  cytochrome C [80] and lactic acid dehydrogenase [82], 
an increased expression of  apototic protease factor-1 [81, 84], an 
activation of  caspase-3 ( needed for cell death) [79], all hallmarks 
of  atherogenesis. When specific inhibitors of  the SMases and 
SPT-1 (and SPT-2) were utilized, in primary cell cultures of  
VSM cells (including those from coronary arteries), exposed 
to low Mg2+ environments, we noted an inhibition and release 
of  ceramides, inhibition of  DNA fragmentation, inhibition 
of  release of  cytochrome C from the mitochondria, reduced 
expression of  protease factor-1, an inhibition of  activation of  
caspase-3, a decreased release of  lactic acid dehydrogenase from 
the heart, reduced lipid peroxidation of  cardiac muscle cells, and 
attenuation of  release/generation of  cytokines and chemokines 
[79-82, 84-86, 96, 97]. Working with perfused rat hearts, our 
laboratories found that low Mg2+ environments caused decreased 
perfusion pressures, decreases in stroke volume, marked decreases 
in coronary arterial flows, decreases in cardiac output, generation 
of  ceramides, reductions in cardiac cellular ATP, phosphocreatine 
and pH [98] and generation of  reactive oxygen species [99]. 
We, thus, believe that , collectively, these new studies on hearts 
and coronary arteries from animals on MgD diets support our 
hypothesis that generation and release of  ceramides are pivotal 
molecules in the initiation of  cellular and molecular events leading 
to coronary arterial (and coronary microcirculatory) ischemic 
changes, eventuating in inflammatory and atherogenic events 
producing atrial arrythmias and fibrillation.
During the performance of  the foregoing in-vivo and in-vitro 
studies , using proton- nuclear magnetic resonance spectroscopy, 
we noted rapid formation of  platelet-activating factor (PAF) and 
PAF-like lipid molecules [74].
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Magnesium deficient environments lead to forma-
tion of  PAF and its potential significance to atrial 
fibrillatory events
PAF is known to play major roles in inflammatory responses and 
atherogenesis [for reviews, see [100-102]]. In addition, PAF is 
known to affect the heart and cardiac muscle cells in numerous 
ways [for reviews, see [101, 102]]. For example, PAF can produce 
coronary arterial vasoconstriction, lower arterial blood pressure, 
increase coronary vascular resistance, release several lipid-like 
molecules from the heart, reduce cardiac output, decrease cardiac 
contractility, alter atrial and papillary muscle chronotropicity and 
membrane action potentials, as well as alter potassium currents in 
isolated cardiomyocytes [for reviews, see [101, 102, 103]]. All of  
these attributes of  PAF's actions on the heart and coronary vascular 
tree certainly would be more than enough to cause profound atrial 
fibrillation. Moreover, a variety of  the circulating blood formed 
elements (e.g., polymorph nuclear leukocytes, platelets, basophils, 
and macrophages) and endothelial cells can elaborate PAF [101, 
102]. Recently, we have found that coronary, cerebral and aortic 
VSM cells can also elaborate and release PAF [103]. There are a 
growing number of  reports that both PAF and ceramides may result 
in transformation of  VSM cells from one phenotype to another, 
as is typically found in the atherosclerotic process [for reviews, 
see [103-106]]. A number of  investigators employing intravital 
microscopy techniques, similar to those used in our laboratories 
[for review, see [103]] have demonstrated that PAF increased the 
number of  white blood cells in the microvessels concomitant with 
intense vasoconstriction-spasms with increasing concentrations 
of  the putative lipid mediator (i.e., PAF), less leukocyte rolling 
, and increased adherence of  the leukocytes to the endothelial 
surfaces with increased vascular-capillary permeability [for review, 
see [103]]. Using open and closed chambers implanted in rodent 
cerebral cortex and skeletal muscles, we have observed similar 
phenomena [103]. Interestingly, we have reported that ceramides 
produce almost similar phenomena in a variety of  microvascular 
beds when studied by high-resolution video microscopy [78, 103]. 
Collectively, these older and newer experimental studies could be 
used to advance our hypothesis that generation and release of  
both PAF and ceramides with underlying MgD states are more 
than likely involved in generation of  atrial fibrillation after cardiac 
and lung surgery and may be major contributors in other types of  
patients presenting with atrial fibrillation.
Importance of  Mg supplemented drinking water 
and beverages for heart health
Over the past two-plus decades, our laboratories have been 
investigating the utility of  Mg-supplemented or naturally-
occurring spring waters to avoid the pitfalls of  dietary-and/
or metabolically-induced MgD-states which affect heart health 
[e.g., see [79-82, 84-86, 96, 97]. Our results, so far, bolster the 
idea that water intake (e.g., from tap waters, well waters, bottled 
waters, beverages using tap/well/spring waters, or desalinated 
waters) in humans should contain at least 25-40 mg/liter/day of  
Mg2+ [107]. A number of  experiments done in our labs indicate 
that most, if  not all of  the cardiovascular manifestations (i.e., 
decreased cardiac output, decreased coronary arterial flows, lipid 
peroxidation of  cardiac muscle membranes, synthesis/release of  
toxic sphingolipids, cytokines and chemokines, mitochondrial 
release of  cytochrome C, increased Ca2+ entry and overload, 
apoptosis, etc) observed in hearts of  experimental animals can 
be prevented or ameliorated when imbibing drinking waters with 
appropriate amounts of  Mg2+ [79-82, 84-86, 96, 97]. We believe 
the latter inclusion in our diets should go a long-way towards the 
prevention and amelioration of  heart arrthymias and fibrillations 
. Instituting such a daily regimen should also prevent a number 
of  underlying risk factors for PAOF (e.g., drinking of  alcoholic 
beverages, excessive smoking, and aging). Interestingly, on the 
basis of  our work in animals, the World Health Organization has 
suggested people should consume drinking waters containing 
our recommended 25-40 mg/liter/day of  Mg2+ [108]. It is our 
hope that a large scale appropriately-controlled clinical trial can 
be instituted in patients scheduled for cardiac and lung surgeries 
to test our hypothesis.
Future considerations
Although the exact underlying cause(s) of  the high frequency of  
PAOF in patients scheduled for heart or lung surgeries remains to 
be determined, a number of  animal models ( in mice, goats, rabbits 
and dogs) have been utilized to gain insights into possible causes 
of  atrial fibrillation (AF) [for reviews, see [2, 4, 5]]. A number of  
these models have employed knock-out and knock-down mice for 
several potential target genes . Several of  these mouse AF models 
could be examined to determine if  they are MgD (particularly 
decreased ionized Mg levels) and have excess PAF and ceramide 
synthesis and release as a test of  our hypothesis. In addition, a 
clinical study should be undertaken to determine ionized Mg 
levels, ceramide levels, and PAF levels prior to and after cardiac 
and lung surgeries to examine any correlations between these 
parameters before (and after surgeries) to frequency of  PAOF. 
Moreover, it would be prudent, we believe, to undertake clinical 
blinded- trials to determine whether pretreatment of  patients, 
scheduled for cardiac or lung surgery, would benefit from 
pretreatment with selective blockers of  ceramide generation/
release and PAF generation/release along with administration of  
oral and intravenous Mg. Only time will tell whether these human 
and animal studies will prove to validate our hypothesis.
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